MCM
MDGL icon

MAI Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

MAI Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130
Closed -$68.1K – 3636
2026
Q1 		$68.1K Buy
130
+63
+94% +$30.1K ﹤0.01% 2049
2025
Q4 		$39K Buy
67
+61
+1,017% +$31.2K ﹤0.01% 2153
2025
Q3 		$2.75K Sell
6
-6
-50% -$2.24K ﹤0.01% 3228
2025
Q2 		$3.63K Buy
12
+5
+71% +$1.49K ﹤0.01% 3193
2025
Q1 		$2.32K Buy
7
+3
+75% +$986 ﹤0.01% 2947
2024
Q4 		$1.24K Buy
+4
New +$1.13K ﹤0.01% 3142

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAI Capital Management's MDGL Position: Q2 2026 in Review

MAI Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 130 shares — an estimated $68.1K sold.

MAI Capital Management first reported a position in MDGL in Q4 2024 and held it in 6 quarters. The position peaked at $68.1K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • MAI Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 130 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $68.1K.
  • MAI Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Madrigal Pharmaceuticals position peaked at $68.1K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.